(Total Views: 487)
Posted On: 09/21/2019 8:48:30 AM
Post# of 154899
Well, this has been an interesting 12 hours...
I believe this registered direct financing is a final push to get over the goal line and cut Paulson out and minimize fees and dilution. I will read the subscription documents with my single cup of coffee this morning.
Here is what I would like to see to ensure I know I am not chasing bad money with good; everyone at the top needs to get some skin in this game NOW.
As a doctor of internal medicine, I believe this drug could have more than 100 indications some years down the road. If each is worth a billion or more, this stock is worth somewhere between $40 and $180 per share. What we have to remember here is this is no Amgen; it is an Immunex in its infancy stage, and when I say that, I mean embryonic. This company has 5-10 employees, yet could become its own giant biotech within 5-10 years. The growth potential here quite frankly is beyond enormous.
I believe this registered direct financing is a final push to get over the goal line and cut Paulson out and minimize fees and dilution. I will read the subscription documents with my single cup of coffee this morning.
Here is what I would like to see to ensure I know I am not chasing bad money with good; everyone at the top needs to get some skin in this game NOW.
As a doctor of internal medicine, I believe this drug could have more than 100 indications some years down the road. If each is worth a billion or more, this stock is worth somewhere between $40 and $180 per share. What we have to remember here is this is no Amgen; it is an Immunex in its infancy stage, and when I say that, I mean embryonic. This company has 5-10 employees, yet could become its own giant biotech within 5-10 years. The growth potential here quite frankly is beyond enormous.
(3)
(0)
